Low-dose topiramate in alcohol dependence a single-blind, placebo-controlled study

Journal of Clinical Psychopharmacology

Volumn 34, Issue 6, 2014, Pages 709-715

  Martinotti, Giovanni ^a   Di Nicola, Marco ^b   De Vita, Ofelia ^b   Hatzigiakoumis, Daniele Stavros ^b   Guglielmo, Riccardo ^b   Santucci, Barbara ^c   Aliotta, Fererica ^c   Romanelli, Roberto ^c   Verrastro, Valeria ^d   Petruccelli, Filippo ^d   Di Giannantonio, Massimo ^a   Janiri, Luigi ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c Villa Silvia Hospital   (Italy)

^d UNIVERSITY OF CASSINO AND SOUTHERN LAZIO   (Italy)

Author keywords

Alcohol dependence; Anticonvulsants; Craving; Topiramate

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPRAZOLAM; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; DIAZEPAM; FATTY ACID; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LORAZEPAM; LOW DENSITY LIPOPROTEIN; PLACEBO; TOPIRAMATE; TRIACYLGLYCEROL; ANTICONVULSIVE AGENT; FRUCTOSE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ALCOHOLISM; ANXIETY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASSESSMENT OF HUMANS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL INSTITUTE WITHDRAWAL ASSESSMENT FOR ALCOHOL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DRINKING BEHAVIOR; DRUG DETOXIFICATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATTY ACID BLOOD LEVEL; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSESSIVE COMPULSIVE DISORDER; OBSESSIVE COMPULSIVE DRINKING SCALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SAMPLE SIZE; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE; SYMPTOM CHECKLIST 90; TRIACYLGLYCEROL BLOOD LEVEL; ANALOGS AND DERIVATIVES; CONTROLLED CLINICAL TRIAL; TREATMENT OUTCOME;

ADULT; ALCOHOLISM; ANTICONVULSANTS; FEMALE; FOLLOW-UP STUDIES; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 84925812271     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000228     Document Type: Article

References (52)

1. Mokdad AH, Marks JS, Stroup DF, et al. Actual causes of death in the United States, 2000. JAMA. 2004;291(10):1238-1245.
2. Mann K. Pharmacotherapy of alcohol dependence: a review of the clinical data. CNS Drugs. 2004;18(8):485-504.
3. Book SW, Myrick H. Novel anticonvulsivants in the treatment of alcoholism. Expert Opin Investig Drugs. 2005;14(4):371-376.
4. Ait-Daoud N,Malcolm RJ Jr, Johnson BA.An overviewofmedications for the treatment of alcohol withdrawal and alcohol dependence with an emphasis on the use of older and newer anticonvulsants. Addict Behav. 2006;31(9):1628-1649.
5. Martinotti G, Di Nicola M, Romanelli R, et al. High and low dosage oxcarbazepine versus naltrexone for the prevention of relapse in alcohol-dependent patients. Hum Psychopharmacol. 2007;22(3):149-156.
6. Martinotti G. Pregabalin in clinical psychiatry and addiction: pros and cons. Expert Opin Investig Drugs. 2012;21(9):1243-1245.
7. Di Nicola M, Martinotti G, Tedeschi D, et al. Pregabalin in outpatient detoxification of subjects with mild-to-moderate alcohol withdrawal syndrome. Hum Psychopharmacol. 2010;25(3):268-275.
8. Edwards S, Kenna GA, Swift RM, et al. Current and promising pharmacotherapies, and novel research target areas in the treatment of alcohol dependence: a review. Curr Pharm Des. 2011;17(14):1323-1332.
9. Johnson BA, Ait-Daoud N. Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients. Curr Pharm Des. 2010; 16(19):2103-2112.
10. Suppes T. Review of the use of topiramate for treatment of bipolar disorders. J Clin Psychopharmacol. 2002;22(6):599-609.
11. Harris M, Chandran S, Chakraborty N, et al. Mood-stabilizers: the archeology of the concept. Bipolar Disord. 2003;5(6):446-452.
12. Martinotti G, Di Nicola M, Tedeschi D, et al. Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial. J Psychopharmacol. 2010;24(9):1367-1374.
13. Kessler RC. The epidemiology of dual diagnosis. Biol Psychiatry.2004; 56(10):730-737.
14. Czuczwar SJ, Patsalos PN. The new generation of GABA enhancers. Potential in the treatment of epilepsy. CNS Drugs. 2001;15(5):339-350.
15. Khan SH,Wright SL, Banigesh A, et al. Antiischemic effects of topiramate in a transient global forebrain ischemia model: a neurochemical, histological, and behavioral evaluation. Neurochem Res. 2003;28(8): 1235-1239
16. Qian J, Noebels JL. Topiramate alters excitatory synaptic transmission in mouse hippocampus. Epilepsy Res. 2003;55(3):225-233.
17. Johnson BA. Uses of topiramate in the treatment of alcohol dependence. Expert Rev Neurother. 2004;4(5):751-758.
18. Johnson BA, Swift RM, Addolorato G, et al. Safety and efficacy of GABAergic medications for treating alcoholism. Alcohol Clin Exp Res. 2005;29(2):248-254.
19. Miranda R Jr, MacKillop J, Monti PM, et al. Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study. Alcohol Clin Exp Res. 2008;32(3):489-497.
20. Likhitsathian S, Saengcharnchai P, Uttawichai K, et al. Cognitive changes in topiramate-treated patients with alcoholism: a 12-week prospective study in patients recently detoxified. Psychiatry Clin Neurosci. 2012; 66(3):235-241.
21. Likhitsathian S, Uttawichai K, Booncharoen H, et al. Topiramate treatment for alcoholic outpatients recently receiving residential treatment programs: a 12-week, randomized, placebo-controlled trial. Drug Alcohol Depend. 2013;133(2):440-446.
22. Biton V, Edwards KR, Montouris GD, et al. Topiramate titration and tolerability. Ann Pharmacother. 2001;35(2):173-179.
23. Parada M, Corral M, Mota N, et al. Executive functioning and alcohol binge drinking in university students. Addict Behav. 2012;37(2):167-172.
24. Green A, Garrick T, Sheedy D, et al. The effect of moderate to heavy alcohol consumption on neuropsychological performance as measured by the repeatable battery for the assessment of neuropsychological status. Alcohol Clin Exp Res. 2010;34(3):443-450.
25. Paparrigopoulos T, Tzavellas E, Karaiskos D, et al. Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study. BMC Psychiatry. 2011;11:41.
26. Sullivan JT, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict. 1989;84(11):1353-1357.
27. Mottola CA. Measurement strategies: the visual analogue scale. Decubitus. 1993;6(5):56-58.
28. Janiri L, Calvosa F, Dario T, et al. The Italian version of the Obsessive-Compulsive Drinking Scale: validation, comparison with the other versions, and difference between type 1-and type 2-like alcoholics. Drug Alcohol Depend. 2004;74(2):187-195.
29. Derogatis LR, Lipman RS, Covi L. SCL-90: an outpatient psychiatric rating scale: preliminary report. In: Guy W, ed. ECDEU Assessment Manual for Pychopharmacology. Revised 1976. Kensington, Maryland; DHEW Publication No. (ADM), 1976:76-338.
30. Spitzer WO, Dobson AJ, Hall J, et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis. 1981;34(12):585-597.
31. Addolorato G, Abenavoli L, Leggio L, et al. How many cravings? Pharmacological aspects of craving treatment in alcohol addiction: a review. Neuropsychobiology. 2005;51(2):59-66.
32. Addolorato G, Leggio L, Agabio R, et al. Baclofen: a new drug for the treatment of alcohol dependence. Int J Clin Pract. 2006;60(8):1003-1008.
33. Volpicelli JR, Alterman AI, Hayashida M, et al. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49(11): 876-880.
34. Gastfriend DR, Garbutt JC, Pettinati HM, et al. Reduction in heavy drinking as a treatment outcome in alcohol dependence. J Subst Abuse Treat. 2007;33(1):71-80.
35. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361:1677-1685.
36. Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007;298(14): 1641-1651.
37. Baltieri DA, Daró FR, Ribeiro PL, et al. Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction. 2008; 103(12):2035-2044.
38. Flórez G, Saiz PA, García-Portilla P, et al. Topiramate for the treatment of alcohol dependence: comparison with naltrexone. Eur Addict Res. 2011; 17(1):29-36.
39. Luykx JJ, Carpay JA. Nervous system adverse responses to topiramate in the treatment of neuropsychiatric disorders. Expert Opin Drug Saf. 2010; 9(4):623-631.
40. Prado-Lima PA. Pharmacological treatment of impulsivity and aggressive behavior. Rev Bras Psiquiatr. 2009;31(2):58-65.
41. Leung KS, Cottler LB. Treatment of pathological gambling. Curr Opin Psychiatry. 2009;22(1):69-74.
42. McElroy SL, Guerdjikova AI, Martens B, et al. Role of antiepileptic drugs in the management of eating disorders. CNS Drugs. 2009;23(2): 139-156.
43. Berlin HA, Koran LM, Jenike MA, et al. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2011;72(5):716-721.
44. Martinotti G, Nicola MD, Reina D, et al. Alcohol protracted withdrawal syndrome: the role of anhedonia. Subst Use Misuse. 2008;43(3-4): 271-284.
45. Kenna GA, Lomastro TL, Schiesl A, et al. Review of topiramate: an antiepileptic for the treatment of alcohol dependence. Curr Drug Abuse Rev. 2009;2(2):135-142.
46. Hatzigiakoumis DS, Martinotti G, Giannantonio MD, et al. Anhedonia and substance dependence: clinical correlates and treatment options. Front Psychiatry. 2011;17(2):10.
47. Martinotti G, Andreoli S, Reina D, et al. Acetyl-L-carnitine in the treatment of anhedonia, melancholic and negative symptoms in alcohol dependent subjects. Prog Neuropsychopharmacol Biol Psychiatry. 2011; 35(4):953-958.
48. Charney DA, Zikos E, Gill KJ. Early recovery from alcohol dependence: factors that promote or impede abstinence. J Subst Abuse Treat. 2010; 38(1):42-50.
49. Cloninger CR, Svrakic DM, Przybeck TR. A psychobiological model of temperament and character. Arch Gen Psychiatry. 1993;50(12):975-990.
50. Martinotti G, Di Nicola M, Tedeschi D, et al. Craving Typology Questionnaire (CTQ): a scale for alcohol craving in normal controls and alcoholics. Compr Psychiatry. 2013;54(7):925-932.
51. Wages NA, Liu L, O'Quigley J, et al. Obtaining the optimal dose in alcohol dependence studies. Front Psychiatry 2012;3:100.
52. Kranzler HR, Covault J, Feinn R, et al. Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am J Psychiatry. 2014; 171(4):445-452.